Texas Capital Bancshares Inc TX bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,170 shares of the company's stock, valued at approximately $273,000.
Several other hedge funds have also made changes to their positions in the stock. Cibc World Markets Corp grew its stake in shares of AstraZeneca by 1.1% in the fourth quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after buying an additional 142 shares in the last quarter. Diversify Wealth Management LLC boosted its holdings in shares of AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company's stock worth $295,000 after buying an additional 153 shares during the period. Veery Capital LLC raised its holdings in AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company's stock valued at $230,000 after acquiring an additional 157 shares during the period. Rehmann Capital Advisory Group lifted its holdings in AstraZeneca by 1.8% during the 3rd quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company's stock worth $788,000 after purchasing an additional 175 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC boosted its position in shares of AstraZeneca by 0.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock valued at $2,313,000 after acquiring an additional 189 shares during the period. Institutional investors own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on AZN. Morgan Stanley began coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $89.75.
Read Our Latest Research Report on AstraZeneca
AstraZeneca Stock Up 2.6 %
AZN traded up $1.72 during midday trading on Monday, reaching $68.01. 5,939,845 shares of the company were exchanged, compared to its average volume of 5,249,754. The company has a market cap of $210.91 billion, a price-to-earnings ratio of 30.09, a price-to-earnings-growth ratio of 1.42 and a beta of 0.49. The company's fifty day moving average price is $73.35 and its 200 day moving average price is $70.83. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. As a group, analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.
AstraZeneca Increases Dividend
The company also recently disclosed a semi-annual dividend, which was paid on Monday, March 24th. Investors of record on Friday, February 21st were paid a $1.03 dividend. This is an increase from AstraZeneca's previous semi-annual dividend of $0.49. The ex-dividend date of this dividend was Friday, February 21st. This represents a yield of 2%. AstraZeneca's dividend payout ratio is presently 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
